natgillin/translations-raw huggingface dataset:
The herbicidal mixtures or compositions according to the invention containing Imazamox as sole component A) and as herbicide(s) of the group B) quinmerac or quinmerac and metazachlor and optionally an herbicide of the group C) (for example those as disclosed in M5 and M5-1 are very suitable for fighting or controlling a broad spectrum of grasses and broadleaf weeds which are accompanying in general the abovementioned crops, e.g. in particular brassica napus (oil seed rape, canola). 
Herbicidne smjese ili kompozicije prema izumu, na primjer smjese koje sadrže imazamoks 1 kloroacetamid (na primjer one kao što su navedene pod MI, M 1-1, M 1-2, M2, M2-1, M3, M3-1, M4, M4-1, M5 i M5-1) su vrlo pogodne za suzbijanje ili za kontrolu širokog spektra trava i širokolisnih korova koji prate općenito gore navedene kulture, npr., posebno Brassica napus (uljana repica, kanola).
The method of claim 1, wherein the NS5B polymerase inhibitor is a nucleotide inhibitor of HCV NS5B polymerase. 
Farmaceutski sastav patentnog zahtjeva 8, gdje je inhibitor NS5B polimeraze nukleotidni inhibitor. sena mnE
The method of claim 1, wherein the fibrotic condition is selected from the group consisting of pulmonary fibrosis, liver fibrosis, and renal fibrosis. 
Spoj za uporabu prema zahtjevu 2, naznačen time da je stanje izabrano iz skupine koja se sastoji od plućne fibroze, jetrene fibroze i očne fibroze.
The method of clause 31, wherein the voltage-gated sodium channel is NaV1.8. A method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia comprising administering to the subject an effective amount of a compound of any one of clauses 1 to 21, an amorphous Form C of clause 22 or 23, a crystalline Form B of any one of clauses 24 to 28, or a pharmaceutical composition of clause 30. 
Spoj ili sol prema bilo kojem od patentnih zahtjeva od 1 do 41 od 6 do $, amorfni oblik prema patentnom zahtjevu 9, kristalni Oblik B prema patentnom zahtjevu 10 ili farmaceutski pripravak prema patentnom zahtjevu 12 naznačen time što je za upotrebu u postupku liječenja ili smanjenja intenziteta boli kod subjekta s kroničnom boli, crijevnom boli, neuropatskom boli, mišićno-skeletnom boli, akutnom boli, upalnom boli, boli zbog raka, idiopatskom boli, boli nakon kirurške intervencije, visceralnom boli, boli zbog multiple skleroze, Charcot-MarieTooth sindroma, inkontinencije, patološkog kašlja ili srčane aritmije.
For 4 mg—10% Nicotine Solution: Dispense the nicotine into a tared bucket. 
Za 4 mg-10% otopine nikotina: Staviti nikotin u menziriranu kantu.
The fan assembly of claim 7, comprising a plurality of guide vanes for guiding the air flow emitted from the diffuser into the duct. 
Ventilatorski sustav prema zahtjevu 8 koji obuhvaća sredstva (122, 126) za vođenje struje zraka emitirane iz difuzora (74) u vod (18).
A composition for use according to claim 2 wherein the subject has a hemoglobin (Hb) level of 130g/L or less. 
Sastav za upotrebu prema patentnom zahtjevu 1 ili 2 za primjenu u inicijalnoj dozi degareliks od 160 do 320 mg;
B is a 5-12 membered carbocyclic or heterocyclic ring; 
B je petero do dvanaesteročlani karbociklički ili heterociklički prsten;
and at least one resin is additionally provided and mixed with said SMGCC of step a) and said pigment of step b). 
zatim dodatno doda najmanje jedna smola i pomiješa s navedenim SMGCC-om iz koraka a) i navedenim pigmentom iz koraka b).
Moreover, phosphorylation by GSK3B of B-catenin, a protein involved in cell survival, results in its degradation by an ubiquitinilation dependent proteasome pathway.Thus, it appears that inhibition of GSK3B activity may result in neurotrophic activity. 
Osim toga, fosforilacija B-katenina, proteina koji sudjeluje u staničnom preživljavanju, pomoću GSK3B, uzrokuje razgradnju tog proteina proteasomskim putom, ovisnim o ubikvitinilaciji. Prema tome, čini se da inhibicija aktivnosti GSK3B može uzrokovati neurotrofnu aktivnost.
the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 or a fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID NO: 129 or a fragment thereof. A recombinant cell expressing the antibody of any one of claims 1-13. A conjugate comprising an antibody of any one of claims 1-13 coupled to a therapeutic agent, wherein the therapeutic agent preferably is a toxin, a radioisotope, a drug or a cytotoxic agent. 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 135 i varijabilno područje lakog lanca koji ima aminokiselinsku sekvencu od SEQ ID NO: 142 naznačeno time da navedena nukleinska kiselina kodira polipeptid, poželjno protutijelo, koje je sposobno vezivati se za CLD18A2 ali ne za CLD18A1 i nakon vezanja za CLD18A2 posreduje u uništavanju stanica koje eksprimiraju CLD18A2 od strane T stanica.
X-Met VI under suitable anhydrous conditions; or 
HR P20100072 TI pod prikladnim anhidridnim uvjetima; ili
Figure 3 is a plan view of a plate-shaped composite structure from which a plurality of arrangements 1 comprising groove structures 4 are produced. 
Slika 3 prikazuje nacrt pločaste kompozitne strukture od koje je izrađeno više naprava 1 koje obuhvaćaju brazdaste strukture 4.
a variant of amino acid residues 20 to 237 of SEQ ID NO: 36, wherein said variant comprises one, two or three conservatively modified amino acid substitutions; 
aminokiselinski ostaci 20 do 237 iz sekv. id. br.: 38 ili njene varijante, pri čemu navedena varijanta sadrži jednu, dvije ili tri konzervativno modificirane aminokiselinske supstitucije.
In certain embodiments, the compositions of the invention are for use in reducing tumor size, reducing tumor growth, or reducing angiogenesis in the treatment of lung cancer. 
Pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je pripravak za upotrebu u postupku liječenja ili sprječavanja raka pluća, raka dojke, raka jetre ili raka debelog crijeva.
In step 230, at least N of a plurality of the nucleic acid molecules contained in the biological sample are randomly sequenced. 
Postupak prema zahtjevu 1, naznačen time, da su molekule nukleinske kiseline iz biološkog uzorka pojačane uporabom lančane reakcije polimeraze.
Figure 16 is distributed by mass of the solution's components, and Figure 17 is distributed by number. 
Slika 16 je distribuirana po masi komponenata otopine, a Slika 17 je distribuirana po broju.
The compound of claim 2 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, malignant ascites, Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, or leukemia. 
Spoj prema patentnom zahtjevu 39, naznačen time što je rak solidni tumor, sarkom, fibrosarkom, osteom, melanom, retinoblastom, rabdomiosarkom, glioblastom, neuroblastom, teratokarcinom, hematopocetski malignitet, maligni ascites, Kaposijev sarkom, Hodgkinova bolest, limfom, mijelom ili leukemija.
• on its top part, two bosses (27) positioned at 180°, 
* - nasvom gornjem dijelu, dvije izbočine (27), koje se nalaze pod 180%;
The PAL variant of item 8, wherein the water-soluble polymer is a polyethylene glycol. 
AVPAL varijanta u skladu s patentnim zahtjevom 4, naznačena time, da je polimer topljiv u vodi polietilen glikol.
a proximal collar fitting (3) and a distal collar fitting (4) interconnected by a small cross-sectional area flexible rubber tube or rod (2) reinforced with a steel or other high strength material mesh, and 
jednu proksimalnu spojnicu (3) i jednu distalnu spojnicu (4) koje su međusobno spojene savitljivom cijevi male površine presjeka ili šipkom (2),
The capsule according to claim 7, wherein the valve means comprise a flexible lip arranged to engage in closure the adjacent wall of the capsule and be biased in opening by effect of the pressure so as to disengage from the adjacent wall. 
Kapsula u skladu s patentnim zahtjevom 7, naznačena time što ventil sadrži fleksibilan rub (15), tako podešen da zatvara susjednu stijenku (6) kapsule, te da se otvara pod djelovanjem tlaka na takav način da se odvoji od susjedne stijenke.
Pharmaceutical composition according to claim 1, wherein the rifamycin SV is contained in an amount of from 10 to 90% by weight. 
Farmaceutski pripravci prema prethodnim patentnim zahtjevima, u kojima je količina sadržanog rifamicina SV od 10 do 90 % masenog udjela.
After stirring for 10 minutes n-butyl lithium (1.6 M in hexanes; 7.3 mL, 11.6 mmol) was added dropwise over 2 minutes then stirring was continued for a further 10 minutes. 
Nakon 10 minuta miješanja n- butillitij (1,6 M u heksanima; 7,3 ml, 11,6 mmol) se ukapava 2 minute, a s miješanjem se nastavi još 10 minuta.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of Claims 1 to 3. 
In vitro metoda proizvodnje aktiviranog citotoksičnog T limfocita (CTL), metoda obuhvaća kontaktiranje CTL-a in vitro s antigenom punim ljudskih MHC molekula klase I s ekspresijom prikladne stanice koja predstavlja antigen na površini za vremensko razdoblje dovoljno za aktiviranje spomenutog CTL-a na način specifičan za antigen, pri čemu je spomenuti antigen peptid sukladno bilo kojoj od Tvrdnji 1 do 3.
is selected from hydrogen, F or Cl; is hydrogen; 
R* je izabran od vodika, F ili CI; R> je vodik;
Thus, the disclosure provides an antibody that binds to an epitope recognised by an antibody having the variable heavy chain sequence recited in SEQ ID NO: 88, and the variable light chain sequence recited in SEQ ID NO: 102. 
(d) varijabilno područje slabog lanca od sekvence SEQ ID NO: 88, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 102;
An all-terrain vehicle according to the claim 1, characterized in that each wheel is mounted on an axle shaft installed within a bearing assembly secured to the frame side members. 
Sveterensko vozilo u skladu s patentnim zahtjevom 1, naznačen time što je svaki kotač (14) montirani na osovinu (12) instaliranu s ležajnim sklopovima (13), pričvršćenim na bočnim elementima kostura (17).
wherein said third polymeric material is a non-ionic polymer and the pH of said inner coating preparation is adjusted prior to coating to be at least 0.5 pH units higher than the pH threshold of the second polymeric material. 
naznačeno time, da je taj treći polimerni materijal je neionski polimer, i navedeni unutarnji pripravak za oblaganje sadrži najmanje jedan aditiv odabran iz puferskog sredstva i baze.
Plates were counted in a Wallac MicroBeta™ plate reader using “Prot. 
Ploče su podvrgnute brojenju u Wallac MicroBeta"" plate čitaču uporabom "Prot.
The invention relates to a strontium-82/rubidium-82 generator, comprising a column filled with a cationic exchanger loaded with strontium-82, and having an inlet and an outlet, and a liquid medium, wherein parts of the column, inlet and outlet coming into contact with the liquid medium are iron-free, preferably metal-free, to a method for producing rubidium-82, and to the obtained diagnostic agent. 
Generator Stroncij-82/Rubidij-82, naznačen time da sadrži kolonu ispunjenu sa kationskim izmjenjivačem ispunjenim sa stroncijem-82, i koji ima ulazni otvor i izlazni otvor, te tekući medij, pri čemu dijelovi kolone, ulazni i izlazni otvor koji dolaze u doticaj sa tekućim medijem su bez željeza, poželjno bez metala, pri čemu tekući medij je elucijski medij za rubidij-82, te je fiziološki pufer koji ima pH od 6-8.5, poželjno pH od 7-8, još poželjnije pH od 7.2-7.4, i pri čemu tekući medij je sterilizacijski medij, poželjno hipokloritna otopina.
THCV alone or in combination with CBD for use in the treatment of generalised seizures and / or partial seizure as claimed in claim 1 or 2 wherein the THCV is present in amount which provides a daily dose of least 1.5mg. 
HR P20140398 T1 PATENTNI ZAHTJEVI Kanabidiol (CBD) za primjenu u liječenju parcijalnih napadaja naznačen time da je CBD prisutan u količini koja osigurava dnevnu dozu od najmanje 400mg.
The method of claim 1 or 2, wherein the immunoglobulin Fc polypeptide comprises at least one of the following mutations: Met252Tyr, Ser254Thr, Thr256G1u, Met428Leu or Asn434Ser. 
Izolirani fuzijski protein za uporabu prema bilo kojem od patentnih zahtjeva 1 do 11, gdje: a. imunoglobulinski Fc polipeptid je modificiran tako da poboljšava vezivanje FcRn; b. imunoglobulinski Fc polipeptid sadrži najmanje jednu od sljedećih mutacija: Met252Tyr, Ser254Thr, Thr256Glu, Met428Leu ili Asn434Ser.
In one embodiment, the human MHC II a extracellular domain in the animal comprises human MHC II a1 and a2 domains; in one embodiment, a non-human portion of the chimeric human/non-human MHC II a polypeptide comprises transmembrane and cytoplasmic domains of an endogenous non-human MHC II a polypeptide. 
U glodavca iz zahtjeva 1. glodavački dio kimernog MHC II a. polipeptida čovjeka/glodavca sadrži transmembranske 1 citoplazmatske domene endogenog MHC II a. polipeptida glodavca i/ili glodavački dio kimernog MHC II BB polipeptida čovjeka/glodavca sadrži transmembranske i citoplazmatske domene endogenog MHC II f3 polipeptida glodavca.
In some embodiments, R1 is C1-4 alkoxy. 
U nekim oblicima, Ri je C,.4 alkoksi.
The method of para 20, further comprising cooling the reaction mixture to a temperature of between 5 degrees Celsius and ambient temperature after lowering the pH of the reaction mixture. 
Postupak prema zahtjevu 12 ili zahtjevu 14, naznačen time da dodatno nakon koncentriranja reakcijske smjese, ili nakon snižavanja pH reakcijske smjese sadrži hlađenje reakcijske smjese do temperature od između 5 stupnjeva Celzija i temperature okoline.
A compound of the formula (2a) wherein R1, R2 and X are as defined in formula (1) of claim 1 and L is a leaving group, provided that when R1 is benzyl, X is oxygen, R2 is methyl then L is not chlorine or when R1 is benzyl, X is a bond, R2 is propyl then L is not chlorine. 
(2a) naznačen time da R!, R*i X su kako je definirano u formuli (1) iz zahtjeva 1 i L je izlazna skupina, uz uvjet da kada R' je benzil, X je kisik, R? je metil tada L nije klor ili kada R! je benzil, X je veza, R? je propil tada L nije klor.
wherein the microfibrillated cellulose has a fibre steepness of from 20 to 50 OR wherein (B) the papermaking composition is substantially devoid of retention aids and wherein the microfibrillated cellulose has a fibre steepness of from 20 to 50. The article, paper product, polymer composition, or papermaking composition of any one of the proceeding claims, wherein: the inorganic particulate material comprises an alkaline earth metal carbonate or sulphate, such as calcium carbonate, magnesium carbonate, dolomite, gypsum, a hydrous kandite clay such as kaolin, halloysite or ball clay, an anhydrous (calcined) kandite clay such as metakaolin or fully calcined kaolin, talc, mica, huntite, hydromagnesite, ground glass, perlite or diatomaceous earth, or combinations thereof; and/or 
Artikl, papirni proizvod, mješavina polimera ili mješavina za proizvodnju papira u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeni time što: anorganski partikulirani materijal sadrži karbonat ili sulfat zemnoalkalnog metala, poput kalcijevog karbonata, magnezijevog karbonata, dolomita, gipsa, hidratiranu kanditnu glinu, poput kaolina, halojzita ili lončarske gline, bezvodnu (kalciniranu) kanditnu glinu, poput metakaolina ili posve kalciniranog kaolina, talk, tinjac, huntit, hidromagnezit, brušeno staklo, perlit ili diatomejsku zemlju, ili njihove kombinacije; i/ili mikrofibrilirana celuloza ima dsg u rasponu od otprilike 25 um do otprilike 250 um, poželjnije od otprilike 30 um do otprilike 150 um, još poželjnije od otprilike 50 um do otprilike 140 um, čak 1 još poželjnije od otprilike 70 um do otprilike 130 um, a najpoželjnije od otprilike 50 um do otprilike 120 um; i/ili mikrofibrilirana celuloza ima monomodalnu raspodjelu veličine čestica ili multimodalnu raspodjela veličine čestica.
Further concentration and final purification are usually carried out by under-vacuum distillation which results to be complicated by severe pyrolytic effects on the unstable unsaturated structures, or by molecular distillation, which limits indeed and yet does not eliminate the thermic degradation and, however, implies expensive plant and managing plant costs and limited productive capacity. 
Daljnje koncentriranje i konačno pročišćavanje se obično izvode destilacijom ispod vakuuma, za koju se ispostavilo da je komplicirana zbog ozbiljnih pirolitičkih učinaka na nestabilne nezasićene strukture, ili molekularnom destilacijom, koja zaista ograničava i još ne eliminira toplinsku degradaciju i ipak uključuje velike troškove postrojenja i upravljanja postrojenjem i ograničeni proizvodni kapacitet.
exchanging heat between the LNG to be supplied to the high-pressure gas injection engine and the boil-off gas generated in the LNG tank. The method according to claim 8 wherein after the boil-off gas exchanges heat with the LNG, the LNG is supplied to the high-pressure gas injection engine, and the boil-off gas is reliquefied and then supplied to the LNG tank. 
ukapljivanje isparenog plina stvorenog u spremniku LNG (1); te izmjenjivanje topline između LNG koji se treba dovesti u visokotlačni plinski injekcijski motor i isparenog plina stvorenog u spremniku LNG (1), naznačen time da nakon što ispareni plin izmjeni toplinu s LNG, navedeni LNG se dobavlja u visokotlačni plinski injekcijski motor, te se ispareni plin ukapljuje i potom vraća u visokotlačni plinski injekcijski motor.
Preferably, the reaction is carried out by reacting a compound of formula II with sodium borohydride in the presence of an alcoholic solvent, optionally mixed with water. Preferred solvent is ethanol. 
Postupak prema zahtjevu 1 gdje se redukcija provodi reakcijom spoja formule II sa natrijevim borohidridom u prisutnosti alkoholnog otapala koje se po izboru miješa s vodom.
The compound according to any one of claims 1 to 6 or the composition according to claim 7, for use in the treatment, in a mammal, preferably a human being, of diseases associated with abnormal fat metabolism, wherein said fat metabolism disease is preferably selected from the group consisting of gout disease, type II diabetes, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, syndrome X, diabetic complications, dysmetabolic syndrome and related diseases, hypercholesterolemia, atherosclerosis, hypertension, pancreatitis, hypertriglyceridemia, hyperlipidemia, stroke, coronary heart diseases, peripheral vascular diseases, peripheral arterial diseases, vascular syndromes, cholesterol-related disorders and drug-induced lipodystrophy. 
Tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 6 ili sastav u skladu s patentnim zahtjevom 7, za uporabu u liječenju, kod sisavaca, poželjno ljudskih bića, bolesti povezanih s abnormalnim metabolizmom masti, pri čemu je navedena bolest metabolizma masti poželjno odabrana iz grupe koja se sastoji od bolesti gihta, dijabetesa tipa II, hiperglikemije, hiperinzulinemije, povišenih razina masnih kiselina ili glicerola u krvi, sindroma X, dijabetičkih komplikacija, dismetaboličkog sindroma i povezanih bolesti, hiperkolesterolemije, ateroskleroze, hipertenzije, pankreatitisa, hipertrigliceridemije, hiperlipidemije, moždanog udara, koronarne bolesti srca, bolesti perifernih žila, bolesti perifernih arterija, vaskularnih sindroma, s kolesterolom povezanih poremećaja i lijekovima inducirane lipodistrofije.
Q represents a C3-8 cycloalkyl group, an aryl group, or a heterocyclic group, wherein the C3-8 cycloalkyl group, the aryl group and the heterocyclic group may be substituted with 1 to 4 substituents which are the same or different and are selected from the group of substituents, Rc, to be shown below, and the heterocyclic group may have the different carbon atoms on the ring bridged with a C1-6 alkylene group or -C1-6 alkylene-O-C1-6 alkylene-, 
W predstavlja RS-X!., x! predstavlja skupinu Cio alkilen, skupinu C2>:o alkenilen, skupinu C2:o alkinilen, skupinu C3g cikloalkilen, skupinu -C14 alkilen-C3.g cikloalkilen-C;.4 alkilen- ili vezu, pri čemu skupina C1.19 alkilen, skupina C2:9 alkenilen, skupina C21o alkinilen, skupina C3g cikloalkilen, i skupina -C;s4 alkilen-C3.g cikloalkilen-C,4 alkilen- mogu biti supstituirane s 1 do 4 supstituenata koji su isti ili različiti i odabrani su iz skupine supstituenata, R", koji će biti prikazani niže,
According to another preferred embodiment of the process according to the present invention, the hydrophobising agent is selected from the group consisting of pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, lauric acid, tridecanoic acid, myristic acid, pentadecanoic acid, palmitic acid, heptadecanoic acid, stearic acid, nonadecanoic acid, arachidic acid, heneicosylic acid, behenic acid, tricosylic acid, lignoceric acid and mixtures thereof, preferably the hydrophobising agent is selected from the group consisting of octanoic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid and mixtures thereof and most preferably the hydrophobising agent is selected from the group consisting of myristic acid, palmitic acid, stearic acid and mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da se hidrofobirajuće sredstvo bira iz skupine koju čine pentanska kiselina, heksanska kiselina, heptanska kiselina, oktanska kiselina, nonanska kiselina, dekanska kiselina, undekanska kiselina, laurinska kiselina, tridekanska kiselina, miristinska kiselina, pentadekanska kiselina, palmitinska kiselina, heptadekanska Kiselina, stearinska kiselina, nonadekanska kiselina, arahidinska kiselina, heneikozilinska kiselina, behenska kiselina, trikozilinska kiselina, lignocerinska kiselina i njihove smjese, poželjno se hidrofobirajuće sredstvo bira iz skupine koju čine oktanska kiselina, dekanska kiselina, laurinska kiselina, miristinska kiselina, palmitinska kiselina, stearinska kiselina, arahidska kiselina i njihove smjese i najpoželjnije se hidrofobirajuće sredstvo bira iz skupine koju čine miristinska kiselina, palmitinska kiselina, stearinska kiselina i njihove smjese.
in a wall of the evacuatable process chamber; and/or 
- < najmanje jednog ispuhivanja i/ili propuhivanja radne komore;
the composition being reconstituted with about 4 ml of water for injection. In this composition the total amount of sodium content of the ceftriaxone sodium and the sulbactam sodium is about 33.075 mg with 1.435 mEq of sodium. 
(o) EDTA u količini od 0.25 mg, spomenuta smjesa je rekonstituirana sa 4+ ml vode za injekcije, i gdje ukupna količina natrija sadržanog u spomenutom ceftriakson natriju i spomenutom sulbaktam natriju iznogi 33.075 mg, uz 1.435 mFq natrija.
More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables prevention and/or treatment of neurodegenerative diseases such as Alzheimer's disease. 
Još specifičnije, cilj je osiguravanje novih spojeva korisnih kao aktivni sastojak lijeka koji omogućuje sprječavanje i/ili liječenje neurodegenerativnih bolesti, poput Alzheimerove bolesti.
The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises about 0.5 mg to about 1000 mg of the crystalline form of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 7-9, naznačen time da navedeni farmaceutski pripravak sadrži od 0.5 mg do 1000 mg kristalnog 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida.